Zomiradomide

N/A

Report date: 2024/12/11 20:00:45
NME

Base Information

Drug NameZomiradomide
Drug Alias NameKT-413KTX-120
ClassificationSmall molecules > Proteolysis-Targeting Chimera (PROTAC)
Mechanisms of ActionInterleukin-1 receptor-associated kinase 4 inhibitors
TargetsInterleukin-1 receptor-associated kinase 4
Therapy Area/IndicationsLymphoma, Large B-Cell, DiffuseLymphoma, Non-HodgkinLymphoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesUnited Kingdom
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesKymera Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesKymera Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsLymphoma, Large B-Cell, DiffuseLymphoma, Non-HodgkinLymphoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A